Tech R&D investments are increasingly looking to tackle issues in cell and gene therapy manufacturing, but is this to the detriment of the wider biomanufacturing space? This panel will discuss whether bioprocess innovation has stalled for 'tried and tested' biologics, and whether technologies and processes being investigated in the advanced therapy space can and will be implemented for more traditional modalities.
Interview Schedule following:
1:45 – 1:55PM: Tom VanCott, Ph.D., Global Head of Product Development, Catalent
1:55 – 2:05PM: Martin Meeson, CEO, FUJIFILM Diosynth Biotechnologies
2:05 – 2:15PM: Daniella Steel,Senior Product Manager, Cell & Gene Therapy, Astrea Bioseparations
2:15 – 2:25PM: TBA
2:25 – 2:35PM: TBA, Samsung Biologics